Logo

American Heart Association

  19
  0


Final ID: MP128

Impact of Left Atrial Strain on Outcomes of Severe Mitral Regurgitation due to Severe Mitral Annular Calcification

Abstract Body (Do not enter title and authors here): Background:
Mitral annular calcification (MAC) is a progressive degenerative condition characterized by calcium deposition along the mitral valve annulus. It is increasingly prevalent in older adults and is associated with elevated morbidity and mortality. However, data on mitral regurgitation (MR) secondary to MAC remain limited. This study aimed to evaluate the prognostic significance of left atrial strain (LAS) and left ventricular global longitudinal strain (LV-GLS) in patients with isolated severe MR due to severe MAC.
Methods:
We conducted a retrospective cohort study at a single tertiary care center. Patients with severe MAC were identified from the institutional echocardiographic database, and those with isolated severe MR were selected for inclusion. The primary endpoint was all-cause mortality. Conventional echocardiographic parameters, LAS, and LV-GLS were recorded. The cohort was stratified by the median reservoir LAS (LASr).
Results:
Between January 2010 and August 2023, a total of 128 patients with isolated severe MR due to MAC were enrolled. Median follow-up period was 134 days (IQR: 33–1,812). The median age was 81 years (IQR: 71–88), and 65% were female. Mean left ventricular ejection fraction (LVEF) was 61% ± 13%; median LV-GLS was -15.4% (IQR: -19.4 to -14.1%) and median LASr was 14.1% (IQR: 10.75–20.0). A total of 45 patients (35.2%) underwent mitral valve (MV) intervention, while 83 patients (64.8%) received conservative management. Among those who underwent intervention, 42 patients (93.3%) underwent surgery and 3 (6.7%) underwent percutaneous mitral clip implantation. Of the surgical cases, 37 underwent valve replacement, including 34 with bioprosthetic valves, and 5 underwent repair. During follow-up, 63 patients (49.2%) died. Outcomes were worse in patients with LASr below the median (p = 0.011), while LV-GLS was not significantly associated with mortality (p = 0.247). Stratification by LASr median and treatment showed best outcomes in those with higher LASr who underwent intervention and worst in those with lower LASr managed conservatively (p < 0.001). In multivariate Cox analysis, each unit decrease in LASr was associated with increased mortality risk (HR: 1.054; 95% CI: 1.002–1.109), while MV intervention reduced mortality (HR: 0.173; 95% CI: 0.075–0.397).
Conclusion:
LASr is associated with all-cause mortality in patients with isolated severe MR due to MAC, and may be a valuable tool for risk stratification.
  • Al Zein, Mohammad  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Okushi, Yuichiro  ( Cleveland Clinic , Beachwood , Ohio , United States )
  • Unai, Shinya  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Pettersson, Gosta  ( CLEVELAND CLINIC FOUNDATION , Cleveland , Ohio , United States )
  • Elgharably, Haytham  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Gillinov, A  ( CLEVELAND CLINIC , Cleveland , Ohio , United States )
  • Grimm, Richard  ( CLEVELAND CLINIC , Chagrin Falls , Ohio , United States )
  • Griffin, Brian  ( CLEVELAND CLINIC , Cleveland , Ohio , United States )
  • Xu, Bo  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Author Disclosures:
    Mohammad Al Zein: DO NOT have relevant financial relationships | Yuichiro Okushi: DO NOT have relevant financial relationships | Shinya Unai: DO have relevant financial relationships ; Consultant:Edwards:Active (exists now) ; Consultant:Artivion:Active (exists now) ; Consultant:Lifenet:Active (exists now) | Gosta Pettersson: No Answer | Haytham Elgharably: DO have relevant financial relationships ; Speaker:Edward's LifeSciences:Active (exists now) ; Speaker:Artivion:Active (exists now) ; Speaker:LifeNet Health:Active (exists now) | A Gillinov: DO have relevant financial relationships ; Consultant:Edwards Lifesciences, Medtronic, Abbott, AtriCure, Artivion, ClearFlow, Johnson and Johnson, Corcym, Baxter:Active (exists now) | Richard Grimm: DO NOT have relevant financial relationships | Brian Griffin: No Answer | Bo Xu: DO have relevant financial relationships ; Speaker:Bristol Myers Squibb:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Imaging in Motion: Multimodality Approach to Valvular Heart Disease

Saturday, 11/08/2025 , 10:45AM - 12:00PM

Moderated Digital Poster Session

More abstracts on this topic:
Association of Race with Disease Expression and Clinical Outcomes among Patients with Mitral Valve Prolapse

Desai Aishwary, Shalaby Alaa, Estes Nathan, Saba Samir, Jain Sandeep, Bhonsale Aditya, Thoma Floyd, Naniwadekar Aditi, Singla Virginia, Wong Timothy, Kancharla Krishna, Mulukutla Suresh, Katz William, Voigt Andrew

A Body Shape Index at Age 25-64 Predicts Mortality and CHD Hospitalization

Shafran Itamar, Krakauer Nir, Krakauer Jesse, Cohen Gali, Gerber Yariv

More abstracts from these authors:
Prognostic Impact of Right Ventricle-Pulmonary Artery Coupling in Patients with Severe Calcific Mitral Stenosis

Okushi Yuichiro, Unai Shinya, Pettersson Gosta, Elgharably Haytham, Gillinov A, Grimm Richard, Griffin Brian, Xu Bo

Impact of Mitral Valve Intervention and Frailty on Outcomes of Severe Mitral Regurgitation due to Severe Mitral Annular Calcification

Al Zein Mohammad, Okushi Yuichiro, Unai Shinya, Pettersson Gosta, Elgharably Haytham, Gillinov A, Grimm Richard, Xu Bo

You have to be authorized to contact abstract author. Please, Login
Not Available